Drug & intervention

glipizide

RxCUI 4821

Clinical trials18
Recruiting0
Related conditions11
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Glipizide

Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. It is used together with a diabetic diet and exercise. It is not indicated for use by itself in type 1 diabetes. It is taken by mouth. Effects generally begin within half an hour and can last for up to a day. Common side effects include nausea, diarrhea, low blood sugar, and headache. Other side effects include sleepiness, skin rash, and shakiness. The dose may need to be adjusted in those with liver or kidney disease. Use during pregnancy or breastfeeding is not recommended. It works by stimulating the pancreas to release insulin and increases tissue sensitivity to insulin. Glipizide was approved for medical use in the United States in 1984. It is available as a generic medication. In 2023, it was the 42nd most commonly prescribed medication in the United States, with more than 15 million prescriptions.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

18 shown
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose ManagementNCT02608177 · 2015-11-01
COMPLETED
Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 DiabetesNCT01758471 · 2012-12-01
UNKNOWN
A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)NCT01698775 · 2012-10-02
COMPLETED
Effect of Exenatide on Liver and Heart Fat and InflammationNCT01951651 · 2010-04-01
COMPLETED
Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) PatientsNCT01020123 · 2009-10-01
COMPLETED
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)NCT00885352 · 2009-04-15
COMPLETED
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes MellitusNCT00856284 · 2009-03-01
COMPLETED
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly DiabeticsNCT00707993 · 2008-06-01
COMPLETED
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes PatientsNCT00660907 · 2008-03-01
COMPLETED
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in HumansNCT01762046 · 2008-01-01
COMPLETED
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)NCT00509236 · 2007-10-19
COMPLETED
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)NCT00509262 · 2007-10-09
COMPLETED
Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)NCT00350779 · 2006-06-12
COMPLETED
Insulin Glargine in Type 2 Diabetic PatientsNCT00347100 · 2006-06-01
COMPLETED
Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 DiabetesNCT00116831 · 2005-01-01
COMPLETED
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)NCT00095056 · 2004-10-01
COMPLETED
Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKANCT00732524 · 2004-09-01
COMPLETED
Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery DiseaseNCT00513630 · 2004-06-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.